Safety Rates Drug Report: adverse events in 2016 Q3 - FDA prescription drugs adverse events in an open, searchable, online, public database

Drug Injury Quarter

Person who experienced the adverse event (patient)

Event ID	CASEID	CASEVERSION	I F COD	EVENT DT	MFR DT	INIT FDA DT	FDA DT	REPT COD	AUTH NUM	MFR NUM	MFR SNDR	LIT REF	AGE	AGE COD	AGE GRP	GNDR COD	E SUB	WT	WT COD	REPT DT	TO MFR	OCCP COD	REPORTER COUNTRY	OCCR COUNTRY
112187025	11218702	5	F	201505	20160915	20150625	20160929	EXP		JP-INCYTE CORPORATION-2015IN002744	INCYTE		75.62	YR		F	Y	53.50000	KG	20160929		MD	JP	JP

Drug(s) used by person

Event ID	CASEID	DRUG SEQ	ROLE COD	DRUGNAME	PROD AI	VAL VBM	ROUTE	DOSE VBM	CUM DOSE CHR	CUM DOSE UNIT	DECHAL	RECHAL	LOT NUM	EXP DT	NDA NUM	DOSE AMT	DOSE UNIT	DOSE FORM	DOSE FREQ
112187025	11218702	1	PS	JAKAFI	RUXOLITINIB	1	Oral	15 MG, BID	300	MG	Y				202192	15	MG	TABLET	BID
112187025	11218702	2	SS	RED BLOOD CELLS, CONCENTRATED	HUMAN RED BLOOD CELL	1	Unknown	2 IU, UNK			D				0	2	IU	INJECTION

Indications of drugs used

Event ID	CASEID	INDI DRUG SEQ	INDI PT
112187025	11218702	1	Myelofibrosis
112187025	11218702	2	Myelofibrosis

Outcome of event

Reactions reported

Event ID	CASEID	PT
112187025	11218702	Cardiac failure
112187025	11218702	Liver disorder
112187025	11218702	Myelofibrosis
112187025	11218702	Pyelonephritis
112187025	11218702	Upper gastrointestinal haemorrhage

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

no results found

Therapies reported

Event ID	CASEID	DSG DRUG SEQ	START DT	END DT	DUR	DUR COD
112187025	11218702	1	20150520	20150529	0
112187025	11218702	2	20150513	20150708	0